Haemophilia in Spain

Haemophilia

Volumn 15, Issue 3, 2009, Pages 665-675

  Aznar, José Antonio ^a   Lucia F ^b   Abad Franch, L ^a   Jimenez Yuste V ^c   Perez R ^d   Batlle, J ^e   Balda, I ^f   Parra, R ^g   Cortina, V R ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Epidemiology; Haemophilia A; Haemophilia B; Spain

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIRETROVIRUS AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; HEPATITIS A VACCINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; AGED; ARTHROPATHY; ARTICLE; BLEEDING; CATHETER INFECTION; CATHETERIZATION; CHILD; DISEASE SEVERITY; GENETIC SCREENING; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; SPAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; EVIDENCE-BASED MEDICINE; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; INFANT; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; QUALITY OF LIFE; SPAIN; YOUNG ADULT;

EID: 65449144323     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02001.x     Document Type: Article

References (37)

1. Evatt BL. World Federation of Haemophilia. Guide to Developing a National Patient Registry. World Federation of Haemophilia 2005. Available at: http://www.wfh.org/2/docs/Publications/ Diagnosis_and_Treatment/Registry_Guide_2005.pdf (last accessed on 11 November 2008).
2. Spooner RJD, Rizza CR. Development of a national database to provide information for the planning of care of patients with congenital blood coagulation defects. In: Rizza CR, Lowe G, eds. Haemophilia and Other Inherited Bleeding Disorders. London: WB Saunders, 1997: 435-53.
3. Larsson SA, Nilsson IM, Blombäck M. Current status of Swedish hemophiliacs. A demographic survey. Acta Med Scand 1982; 212: 195-200.
4. Windyga J, Lopaciuk S, Stefanska E et al. Haemophilia in Poland. Haemophilia 2006; 12: 52-7.
5. Ivaskevicius V, Jurgutis R, Rost S et al. Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data. Br J Haematol 2001; 112: 1062-70.
6. Walker I, Pai M, Akabutu J et al. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion. 1995; 35: 548-51.
7. Tagliaferri A, Rivolta GF, Biasoli C et al. A web-based registry of inherited bleeding disorders in the region of Emilia-Romagna: Results at three and a half years. Haemophilia 2008; 14: 343-54.
8. Koumbarelis E, Rosendaal FR, Gialeraki A et al. Epidemiology of haemophilia in Greece: An overview. Thromb Haemost 1994; 72(6): 808-13.
9. Iorio A, Oliovecchio E, Morfini M, Mannucci PM, on behalf of the Association of Italians Haemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53.
10. Rezende SM, Pinheiro K, Caram C et al. Registry of inherited coagulopathies in Brazil: First report. Haemophilia 2009; 15: 142-9.
11. Rizza CR, Spooner RJD, Giangrande PLF, on behalf of the UK Haemophilia Centre Directors'Organisation. Treatment of haemophilia in the United Kingdom 1981-1996. Haemophilia. 2001; 7: 349-59.
12. Walker IR, Julian JA, Association of Haemophilia Clinic Directors of Canada. Causes of death in Canadians with haemophilia 1980-1995. Haemophilia. 1998; 4: 714-20.
13. Aznar JA, Magallón M, Querol F, Gorina E, Tusell JM. The orthopaedic status of severe haemophiliacs in Spain. Haemophilia 2000; 6: 170-6.
14. White GC, Rosendaal F, Alerdot LM et al. Scientific and Standardization Committee Communication: Definitions in Haemophilia. On behalf of the Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
15. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153-9.
16. Donadle-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-7.
17. Soucie JM, Evatt B, Jackson D, the Hemophilia Surveillance System Project Investigators. Occurrence of Hemophilia in the United States. Am J Hematol 1998; 59: 288-94.
18. Blanchette VS, McReady M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with hemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9(Suppl 1): 19-26.
19. Kasper CK, Lin JC. Prevalence of sporadic and familial haemophilia. Haemophilia 2007; 13: 90-2.
20. Asatiani E, Kessler CM, on Behalf of the Directors of the Comprehensive Hemophilia Treatment Centers in Region III. Multiple congenital coagulopathies co-expressed with von Willebrand's disease: The experience of Haemophilia Region III Treatment Centers over 25years and review of literature. Haemophilia 2007; 13: 685-96.
21. Margaglione M, Castaman G, Morfini M et al. The Italian AICE-genetics haemophilia database: Results and correlation with clinical phenotype. Haematologica 2008; 93: 722-8.
22. Ljung R, Petrini P, Tengtborn L, Sjörin E. Haemophilia B mutations in Sweden: A population-based study of mutational heterogeneity. Br J Haemat 2001; 113: 81-6.
23. Tagariello G, Belvini D, Salviato R et al. The Italian haemophilia B mutation database: A tool for genetic counselling, carrier detection and prenatal diagnosis. Blood Transfus 2007; 5: 158-63.
24. Plug I, van der Bom JG, Peters M et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004; 104: 3494-500.
25. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of ortopedic status of severe haemophilia A and B patients in France. Haemophilia 2000; 6: 23-32.
26. Gerahty S, Dunkley T, Harrington C, Lindvall K, Maash J, Sek J. Practice patterns in haemophilia A therapy-global progress towards optimal care. Haemophilia 2006; 12: 75-81.
27. Biss TT, Chan AK, Blanchette VS et al. The use of prophylaxis in 2663 children and adults with haemophilia: Results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia, 2008; 14: 923-30.
28. Arnold DM, Julian JA, Walker IR. Mortality rates and causes of death among all HIV-positive individuals with haemophilia in Canada over 21years of follow-up. Blood 2006; 108: 460-4.
29. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46.
30. Sultan Y, the French Haemophilia Study Group. Prevalence of inhibitors in a population of 3.435 haemophilia patients in France. Thromb Haemost 1992; 67: 600-2.
31. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: Results of a large-scale North-America survey. Haemophilia 1996; 2: 28-31.
32. Oldenburg J, Schaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the "Bonn protocol": predictive parameter for therapy duration and outcome. Vox Sang 1999; 77(Suppl 11): 49-54.
33. Di Michele DM, Kroner BL, the North American Immune Tolerance Study Group. The North American immune tolerance registry: Practices, outcomes, outcome Predictors. Thromb Haemost 2002; 87: 52-7.
34. Auerswald G, Von Depka Prondzinski M, Ehlken B et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004; 10: 499-508.
35. Instituto Nacional de Estadística. Censo de la Población Española, 2007. http://www.ine.es/ (last accessed on 15 December 2008).
36. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2008; 14: 671-84.
37. Batlle J, Villar A, Liras A et al. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. Blood Coagul Fibrinolysis 2008; 19: 333-40.